• Mashup Score: 1

    Another huge month in European Urology and we bring you selected highlights here on the European Urology podcast. Co-hosts Professor Declan Murphy (Melbourne…

    Tweet Tweets with this article
    • In the EU podcast this month, @NikitaB0709 previews some of the highlights from the October issue. Don't forget to check out the podcast here: https://t.co/dNubCEEWvN You can also check out the highlights from our October issue here: https://t.co/Q6e28hOLZs #UroSoMe https://t.co/Y6zQrnuCwT

  • Mashup Score: 2

    The European Randomized Study of Screening for Prostate Cancer (ERSPC), the only sufficiently powered trial, showed, besides a 20% reduction in prostate cancer mortality in the intervention arm, that many men needed to be screened and to be treated to avoid one prostate cancer death [1]. Since that publication, it has been stated many times that prostate cancer screening can be performed more efficiently and should lead to less overdiagnosis than was initially designed. An early stopping age and limiting the number of tests to three or four are (cost-)effective ways to improve the balance between harms and benefits [2].

    Tweet Tweets with this article
    • Wise Prostate-specific Antigen Testing Means a Limited, Risk-adjusted, and Personal Approach https://t.co/7CPKi9ZMAs #Medtwitter #UroSoMe

  • Mashup Score: 1

    Obesity and its metabolic sequelae are risk factors for prostate cancer progression. Obesity results in altered secretion of adipokines (leptin, adiponectin, vascular endothelial growth factor, interleukin 6), which may contribute to the molecular association between obesity and prostate cancer.

    Tweet Tweets with this article
    • Throwback Thursday: Obesity and Prostate Cancer: A Role for Adipokines https://t.co/d0twAhaFLV #prostatecancer #UroSoMe #Medtwitter https://t.co/IZ9ksEtt6O

  • Mashup Score: 0

    Pamela L. Kunz, MD, Yale University School of Medicine, New Haven, CT, talks on the challenging of managing endocrine tumors, including determination of treatment sequencing. Patients with low-grade or slow growing endocrine tumors tend to be treated with first-line somatostatin analogues, such as octreotide or lanreotide, with options expanding within the second-line treatment setting. Upcoming trials are utilizing comparator arms, including a Phase II trial (NCT05247905) comparing capecitabine plus temozolomide to lutetium Lu 177-dotatate in advanced pancreatic neuroendocrine tumors. Such trials enables comparison of active agents which has previously been lacking in the field. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.

    Tweet Tweets with this article
    • 🎥@PamelaKunzMD of @YaleMedicine discusses challenges in endocrine tumor management and exciting upcoming trials to compare treatments: ➡️https://t.co/h6MLQMl3YL #PancSM #UroOnc #UroSoMe

  • Mashup Score: 10

    Botulinum toxin is a presynaptic neuromuscular blocking agent inducing selective and reversible muscle weakness up to several months when injected intramuscularly in minute quantities. Different medical disciplines have discovered the toxin to treat mainly muscular hypercontraction. In urology, indications for botulinum-A toxin have been neurogenic detrusor overactivity, detrusor-sphincter dyssynergia, motor and sensory urge and, more recently, chronic prostatic pain.The available literature was reviewed using Medline Services.

    Tweet Tweets with this article
    • Throwback Thursday: Botulinum Toxin as a New Therapy Option for Voiding Disorders: Current State of the Art https://t.co/u2YZ3Jazgb @ReitzAndre #UroSoMe #Medtwitter https://t.co/CkkECJgkQB

  • Mashup Score: 0

    Anusha Chidharla, MBBS, University of Kansas Medical Center, Kansas City, MO, compares the real-world data of belzutifan in VHL-associated tumors versus clinical trial data. The objective response rate (ORR) for associated renal cell cancer was 23%, lower than the clinical trial’s 49%, likely due to shorter follow-up duration (8 months vs. 21 months) and less frequent scans. Safety findings were similar, with common side effects being anemia and fatigue (65-70%). Belzutifan dose was decreased in 30% of our patients (vs. 15% in the clinical trial) due to poorer performance status (ECOG 1-2 vs. ECOG 0). These results highlight the importance of longer follow-up and more frequent scans to capture treatment responses accurately in the real-world setting. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world

    Tweet Tweets with this article
    • 🎥Anusha Chidharla, MBBS, of @KUMedCenter presents real-world data on belzutifan in VHL-associated tumors, highlighting the need for longer follow-up and more scans for accurate treatment assessment: ➡️https://t.co/krZX6On1k4 #ASCO23 #UroOnc #UroSoMe